Malignant Solid Neoplasm — Trials

Malignant Solid Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 429
Recruiting: 209
Ph III recruiting: 10
Growth YoY: +2.3%
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: 29.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (101)

clinicaltrialsPublishedShowing 51–58 of 58 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03830918	Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy	active not recruiting	Phase 1 / Phase 2	59	Jonsson Comprehensive Cancer CenterOTHER	1	Feb 12, 2026	clinicaltrials
NCT04459273	Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC)	active not recruiting	Phase 1	26	Jonsson Comprehensive Cancer Center